Epidiolex

Jul 03, 2026

Developmental and epileptic encephalopathies (DEEs) have evolved from symptom control toward precision neurology, with the market anchored by EPIDIOLEX (cannabidiol, Jazz Pharmaceuticals), initially approved in the US in 2018 for Dravet syndrome and Lennox–Gastaut syndrome (LGS) and later expanded to tuberous scler...

Nov 16, 2020

Potential and growth of the current market The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the l...

Apr 03, 2019

What exactly is Marijuana? In a layman language, Marijuana is the dried buds and leaves of a plant Cannabis sativa favored in warm, wild tropical climates. Earning names like pot, ganja, weed, hemp, hash, etc. it contains around 104 active cannabinoids (CBD). What they do is, they mimic the signal producing che...

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Sep 30, 2016

GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards approval of Epidiolex, as seen in the announcement of positive phase 3 trial results earlier this week. The drug is fo...